Drug repurposing screens identify compounds that inhibit α-synuclein oligomers' membrane disruption and block antibody interactions-Reference-Cited by-同舟云学术

Drug repurposing screens identify compounds that inhibit α-synuclein oligomers' membrane disruption and block antibody interactions

Published:2023 Issue:11 Volume:14 Page:3030-3047
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Somavarapu Arun Kumar¹,Kleijwegt Giulia¹,Nagaraj Madhu¹,Alam Parvez¹,Nielsen Janni¹,Otzen Daniel E.¹^ORCID

Affiliation:

1. Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark

Abstract

The toxic α-synuclein oligomer (αSO) is an important drug target. Neuronal proteins found by pull-down assays do not bind αSO in solution. A liposome assay identifies 7 drugs reducing αSO membrane disruption, of which 2 disrupt αSO-antibody binding.

Funder

Natur og Univers, Det Frie Forskningsråd

Novo Nordisk Fonden

Lundbeckfonden

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/SC/D2SC05534A

Reference65 articles.

1. Alzheimer's Disease and Parkinson's Disease

2. Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders

3. Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease

4. In vivo demonstration that -synuclein oligomers are toxic

5. Calcium is a key factor in α-synuclein induced neurotoxicity

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibodies and α-synuclein: What to target against Parkinson's Disease?;Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics;2024-02